Your AI-Trained Oncology Knowledge Connection!

Opinion

Video

Selinexor Plus Ruxolitinib in JAK Inhibitor-Naïve Patients: Updated Results From XPORT-MF-034

Author(s):

Andrew Kuykendall, MD,Raajit K. Rampal, MD, PhD

Andrew Kuykendall, MD, highlights the potential of selinexor plus ruxolitinib in JAK inhibitor-naïve patients with MF based on promising response rates in XPORT-MF-034 updated results, with plans for a phase 3 study. He also noted the need to manage nausea as a adverse effect.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!
Related Videos
Seema A. Bhat, MD, a hematologist at The Ohio State University Comprehensive Cancer Center—James; as well as an assistant professor in the Department of Internal Medicine in the Division of Hematology at The Ohio State University
Raajit Rampal, MD, director of the Center for Hematologic Malignancies and director of the Myeloproliferative Neoplasms Program at Memorial Sloan Kettering Cancer Center
Grzegorz S. Nowakowsi, MD, a consultant in the Division of Hematology in the Department of Internal Medicine and the Enterprise Deputy Director of Clinical Research at the Mayo Clinic Comprehensive Cancer Center
Julie M. Vose, MD, MBA
6369343864112
Marco Davila, MD, PhD, the senior vice president and associate director for Translational Research in the Department of Medicine, as well as the Rustum Family Endowed Chair in Translational Research at Roswell Park Comprehensive Cancer Center
Nikolai Podoltsev, MD, PhD of Yale Cancer Center
Nirav Shah, MD, MSHP, discusses evaluating zamtocabtagene autoleucel in patients with relapsed/refractory diffuse large B-cell lymphoma.
Carrie L. Kitko, MD
Peter Riedell, MD
Related Content
R/R DLBCL | Image Credit: © LASZLO - stock.adobe.com
March 20th 2025

FDA Grants Fast Track Designation to Azer-Cel for R/R DLBCL

Paul J. Shaughnessy, MD, medical director, Adult Blood and Marrow Stem Cell Transplant Program, Methodist Hospital
November 28th 2024

FDA Approval Insights: Obe-Cel in B-Cell Precursor ALL

Orca-T in Hematologic Malignancies
March 17th 2025

Orca-T Improves cGVHD-Free Survival in Advanced Hematologic Malignancies

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

Acute Myeloid Leukemia | Image Credit: © stock.adobe.com
March 12th 2025

INB-100 Following HSCT Displays Long-Lasting Activity in Pretreated AML

Cema-Cel in R/R LBCL | Image Credit: © LASZLO – stock.adobe.com
March 11th 2025

Cema-Cel Induces CRs and Has Manageable Safety Profile in CD19 CAR T-Cell Therapy–Naive R/R LBCL